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health records
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Abstract
Background: COPD is a highly heterogeneous disease composed of different phenotypes with different
aetiological and prognostic profiles and current classification systems do not fully capture this heterogeneity. In this
study we sought to discover, describe and validate COPD subtypes using cluster analysis on data derived from
electronic health records.
Methods: We applied two unsupervised learning algorithms (k-means and hierarchical clustering) in 30,961 current
and former smokers diagnosed with COPD, using linked national structured electronic health records in England
available through the CALIBER resource. We used 15 clinical features, including risk factors and comorbidities and
performed dimensionality reduction using multiple correspondence analysis. We compared the association
between cluster membership and COPD exacerbations and respiratory and cardiovascular death with 10,736 deaths
recorded over 146,466 person-years of follow-up. We also implemented and tested a process to assign unseen
patients into clusters using a decision tree classifier.
Results: We identified and characterized five COPD patient clusters with distinct patient characteristics with respect
to demographics, comorbidities, risk of death and exacerbations. The four subgroups were associated with 1)
anxiety/depression; 2) severe airflow obstruction and frailty; 3) cardiovascular disease and diabetes and 4) obesity/
atopy. A fifth cluster was associated with low prevalence of most comorbid conditions.
Conclusions: COPD patients can be sub-classified into groups with differing risk factors, comorbidities, and
prognosis, based on data included in their primary care records. The identified clusters confirm findings of previous
clustering studies and draw attention to anxiety and depression as important drivers of the disease in young,
female patients.
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Background
Chronic obstructive pulmonary disease (COPD) is respon-
sible for considerable morbidity, mortality and health care
expenditure worldwide. The estimated prevalence of COPD
is about 1% in the general population and is increasing,
projected by 2030 to be the third leading cause of death
and the seventh leading cause of disability adjusted life
years (DALYs) lost globally [1, 2]. Exacerbations of COPD
are the second commonest cause of medical hospital ad-
mission in the UK with 8% of patients dying during an ad-
mission and 23% within a year of admission [3].
COPD is clinically heterogeneous [4]. Patients have
different phenotypes with different aetiological and prog-
nostic profiles and current disease classification systems
do not fully capture this heterogeneity. Simple clinical
measures such as the forced expiratory volume in one
second (FEV1) and the number of acute exacerbations
remain the best tools for disease staging as set out in the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) strategy [5]. However, it is increasingly recog-
nised that treatment efficacy varies widely between indi-
viduals, and yet strategies are not informed by a detailed
understanding of the underlying pathobiological mecha-
nisms, therefore failing to alter the underlying causes of
the disease but instead mostly address symptoms. There
is an urgent need to identify, characterize and under-
stand COPD subtypes in order to design, develop and
evaluate more effective therapeutic strategies [6].
Previous COPD phenotyping studies have mostly fo-
cused on small, highly-selected populations with relatively
short follow-up periods rather than population-based co-
horts of COPD patients with extensive longitudinal infor-
mation [7–12]. Typically, these studies underrepresent
some demographic groups, such as female and GOLD 1
stage patients. The clinical markers included in these ana-
lyses exhibit great variation, and are often not collected in
a primary care setting.
Using data from routinely collected electronic heath re-
cords (EHR) can potentially enable the identification of
COPD subtypes that are representative of all COPD pa-
tients and provide higher-resolution longitudinal markers
of comorbidity, disease severity and progression.
The objective of this study was to discover, describe and
test the reproducibility of COPD subtypes by applying clus-
ter analysis methods on large-scale EHR data. In order to
assess the reproducibility of clusters, part of the data was
set aside and only used to replicate the analysis findings.
Methods
Data sources
We selected anonymized patient EHR from the CALIBER
resource described [13, 14] and validated [15] elsewhere.
Briefly, the CALIBER resource is built on longitudinal
structured records from three national sources for research:
The Clinical Practice Research Datalink (CPRD), Hospital
Episode Statistics (HES), and cause-specific mortality from
the Office for National Statistics (ONS). CPRD provides an-
thropometric measurements, laboratory tests, clinical diag-
noses, symptoms, prescriptions, and medical procedures,
coded with the Read controlled clinical terminology. The
primary care practices in CPRD and the subset of linked
practices used in the present analysis are representative of
the UK primary care setting [16] and have been validated
for epidemiological research [17]. HES provides informa-
tion about diagnoses (coded with the tenth revision of the
International Classification of Diseases [ICD-10]) and
medical procedures (coded with the 4th revision of the
OPCS Classification of Interventions and Procedures)
related to all elective and emergency hospital admissions
across all National Health Service (NHS) hospitals in
England. ONS provides a national mortality registry with
physician-certified causes of death (coded using ICD-9 and
ICD-10). All data sources were linked with a deterministic
algorithm using patients’ NHS number (unique ten-digit
identifier assigned at first interaction with the healthcare
system), date of birth, sex and postcode which has been
previously validated [17].
Study population
The study period was January 1st 1998 to January 3rd 2016,
and individuals were eligible for inclusion if: a) they were
(or turned) 35 years of age or older during the study period,
b) they had been registered for at least one year in a pri-
mary care practice which met research data recording stan-
dards (known as Up To Standard and defined using CPRD
algorithms examining patterns of data completeness and
temporal gaps in recording) and c) had at least one diag-
nostic code for COPD. We did not impose an upper age
limit. We used an open cohort design, so patients entered
the study when they met the inclusion criteria. We set the
index date for each participant to the date of the first
COPD diagnostic code recorded in primary care while the
participant was eligible. Patients were censored on the earli-
est date among the following: a) death from any cause (as
defined in ONS or CPRD), b) leaving the primary care
practice or c) the last practice data collection. In the ana-
lysis of all-cause mortality and cumulative hospitalisations,
patient data derived from HES and ONS sources beyond
the censoring date in the original analysis were used where
available. Patients with missing baseline data were excluded
from the analysis (Fig. 1).
COPD definition
We have used validated algorithms and robust pheno-
typing approaches which have been evaluated and pub-
lished previously. COPD diagnosis specifically was based
on a validated algorithm (86.5% PPV) and used in over
50 publications [18] combined with either a current or
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former smoking status. The specific COPD definition
READ codes are given in the Additional file 1 Given
that the prevalence of COPD in never-smokers is less
than 5 % in the UK, we did not include never-smokers,
in order to minimise the chances of including patients
who were misdiagnosed with COPD and to ensure
alignment with UK clinical guidelines on the diagnosis
of COPD by NICE [19]. Patients with a diagnosis of
asthma were included, as it is possible to have both dis-
eases and they co-occur in about 14% of patients with
COPD [20].
Cluster-generating features
The following baseline features used in generating the clus-
ters were defined from the CPRD, recorded during primary
care consultations: Body mass index (BMI), smoking status
(current or ex), atopy, airflow obstruction as defined by Glo-
bal Initiative for Chronic Obstructive Lung Disease (GOLD)
stage [21]: 1 (FEV1% predicted > = 80%), 2 (50% <= FEV1%
predicted < 80%), 3 (30% <= FEV1% predicted < 50%) and 4
(<= FEV1% predicted < 30%)– and eosinophil % of white
blood cell counts, gastro-esophageal reflux disease (GERD),
chronic rhinosinusitis (CRS), diabetes, anxiety, depression, is-
chemic heart disease (IHD), hypertension, heart failure. For
sex, the value recoded in the patient demographic table by
the general practitioner (GP) was used and for height we
used the most recent value available.
We classified COPD therapy type with regards to differ-
ent combinations of inhaled corticosteroids (ICS), Long
Acting Muscarinic Antagonists (LAMA) and/or Long
Acting Beta-2 Antagonists (LABA) as: a) no therapy
(none of LAMA, LABA prescribed), b) mono-therapy
(prescription of LABA or LAMA only), c) dual therapy
(prescription of either LABA&LAMA or LABA&ICS or
LAMA&ICS), and c) triple therapy: prescription of all
LABA, LAMA and ICS.
Phenotyping algorithms for the covariates and comorbidi-
ties described here were defined using previously-published
phenotyping algorithms from the CALIBER resource which
have been used in over 60 publications using robust method-
ologies [15, 22–25].
Supplementary variables
The following were supplementary variables, extracted from
the EHR but not used in the generation of clusters: a) Age at
index (diagnosis date) b) asthma diagnosis (stratified as pre
−/post-COPD diagnosis or at any time), c) modified Medical
Research Council (mMRC) dyspnoea scale, d) health
utilisation quantified as the rate of consultations with clinical
contact in the last year before index date and the last three
years before the index date, e) deprivation. Socioeconomic
Fig. 1 Main experiment steps (1) Split cohort into Training and Test sets; (2) Apply multiple correspondence analysis (MCA) to the Training set using all 15
potential cluster-generating features, results in 3 components; (3) Use 3 components derived in Step 2 from MCA analysis in k-means algorithm, results in
k = 5 clusters; (4) Split Training set into a decision tree classifier (DTC) Training and DTC Test set to predict cluster labels obtained from k-means algorithm;
(5) Train and validate DTC; (6) Apply DTC to Test set to predict cluster labels; (7) Apply MCA to Test set as in Step 2, results in 3 components; (8) Use 3
components derived in Step 7 from MCA analysis in k-means algorithm, results in k = 5 clusters; (9) Compare cluster assignments in Test set from Steps 6
and 8 by calculating the Jaccard Index (% of patients overlapping in the same cluster between the two solutions)
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deprivation, divided into quintiles, was measured using the
Index of Multiple Deprivation (IMD), a neighbourhood
deprivation score combining indices of unemployment,
crime, income, education and other markers of social in-
equality [26].
Clinically relevant events associated with cluster
assignment
We used an a priori- specified set of clinically-relevant
features to evaluate and interpret (but not to generate)
clusters: a) rate of severe (resulting in a hospital admis-
sions) or moderate (resulting in a primary care consult-
ation) acute COPD exacerbation (AECOPD), b)
respiratory and cardiovascular-related mortality and
underlying cause of death. AECOPD recorded in
primary and hospital care were identified using
previously-validated phenotyping algorithms, using a
combination of symptoms, antibiotics and oral cortico-
steroid prescriptions (excluding rescue packs) as well as
codes for lower respiratory tract infections [3, 27]. All
variables and outcomes are summarised in Additional
file 1: Tables S1 and S2.
Statistical methods
The main experiment has been outlined in Fig. 1. We
randomly split the data into a training set (75%) and
test set (25%). Statistical analyses described below
were performed on the training data only unless
otherwise specified. We performed multiple corres-
pondence analysis (MCA [28]) using all covariates,
transforming the three numerical covariates (BMI,
FEV1% predicted and eosinophils) into categorical.
This was deemed acceptable given that commonly
used categories exist for BMI, COPD severity (indi-
cated by the GOLD stage) and high eosinophil
threshold. The MCA step resulted in a set of numer-
ical components ranked by percentage of explained
variance. The advantage of using the MCA compo-
nents as input to the clustering algorithm instead of
the original variables is that the components are con-
tinuous and orthogonal to each other as well as
centred around zero with similar standard deviations.
In particular, k-means requires continuous features on
comparable scales so as to not be biased towards fea-
tures with large value ranges. Using orthogonal (un-
correlated) features ensures that highly correlated
variables do not dominate cluster assignments.
Clustering methods are a set of computational tech-
niques that identify subsets in high-dimensional vari-
able spaces by grouping according to their similarity.
Such methods have been previously successfully ap-
plied to sub-phenotyping studies [12, 29]. We applied
k-means and hierarchical clustering (HC) algorithms
[30] on the numerical components resulting from the
MCA step, using the distance between points in
Euclidean space as the distance metric for both
methods. Cluster-wise stability was assessed through
resampling 30% of the training dataset 100 times and
computing the Jaccard similarities [31] to the original
clustering results. The Jaccard similarity or Jaccard
index is a simple metric for the overlap of
data-points between two clustering solutions. If a high
proportion of patients are regularly clustered together
the Jaccard similarity will be high.
We iteratively applied k-means clustering examining dif-
ferent values of k between 2 and seven and based the final
choice of clusters on the average best silhouette coefficient
[32]. Silhouette is a method of interpretation and valid-
ation of consistency within clusters. The technique pro-
vides a succinct graphical representation of how well each
object lies within its cluster. The silhouette value is a
measure of how similar an object is to its own cluster (co-
hesion) compared to other clusters (separation). A precise
definition is given in the Additional file 1, section 3. The
silhouette ranges from − 1 to 1, where a high value indi-
cates that the object is well matched to its own cluster
and poorly matched to neighbouring clusters. A negative
value indicates that a data point would be more appropri-
ately classified in its neighbouring cluster. The silhouette
coefficient is calculated as the average silhouette of all the
data in the dataset.
We used descriptive statistics to summarise and
compare demographic characteristics, risk factors and
clinical covariates within and between clusters and
assigned cluster labels manually based on clinical
input.
Evaluation
Clusters were evaluated on the basis of results obtained from
the training dataset. In order to test the reproducibility of the
resulting five clusters on the test dataset, we trained a
non-parametric decision tree classifier (DTC) [33], using the
labels acquired from the clustering process, and validated the
model on the remaining subset. More details on the DTC
training process are included in the Additional file 1. In
order to evaluate the robustness of our results, we repeated
the experiment (MCA/k-means clustering) to the test set
and compared the concordance of the acquired clusters with
the cluster labels predicted by the DTC.
We obtained hazard ratios for the association between
cluster label and time-to-CVD and respiratory-related
mortality, adjusted for baseline age. We compared cu-
mulative AECOPD between clusters.
Given the high levels of asthma misdiagnosis in this cohort,
and in order to investigate the impact of removing all patients
with potential asthma-COPD overlap, we performed a sensi-
tivity analysis by repeating the analyses excluding all patients
with diagnostic codes for asthma and compared our findings.
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All analyses were performed using Python version 2.7
and relevant open-source libraries: scikit-learn, scipy,
pandas and numpy.
Results
Cohort characteristics
The study was comprised of 30,961 patients from 393 pri-
mary care practices contributing 146, 466 person-years of
follow up. The inclusion and exclusion of patients in/from
the study is described in Fig. 2.
The characteristics of the patients included overall as
well as split by the training and testing datasets are
shown in Table 1.
Cluster analysis
MCA resulted in three numerical factors, the first two of
which explained 89% of the variance. The factor loadings
and contributions of each variable as well as a scatter dia-
gram of the first two factors for each diagram are included in
the Additional file 2 (variable loadings) and Additional file 1:
Figure S1 respectively. We used the three first factors as in-
put to the clustering algorithms.
Both k-means and HC identified five clusters as the
optimal number based on the silhouette criterion. The
clusters obtained using the k-means algorithm had a
higher average silhouette coefficient, with fewer negative
samples, as shown in Fig. 3. Results obtained across both
algorithms broadly displayed concordant patterns of
clinical characteristics with regards to input and valid-
ation covariates. However, HC results tended to be un-
stable i.e. resampling the dataset produced significantly
different results with regards to the optimal number of
clusters and cluster membership. Conversely, in the case
of k-means, after resampling 30% of the dataset 100
times and repeating both the MCA and k-means
process, the Jaccard index, defined as the percentage of
patients that are reassigned in the original clusters, was
calculated at over 89%, showing adequate stability with
regards to the original solution.
Table 2 contains the overall characteristics of patients be-
longing to the clusters in the training dataset. Subgroups
were broadly labelled according to the dominant comorbidi-
ties of patients assigned to them as follows: Cluster 1 -
Anxiety/Depression predominant, Cluster 2 - Non-comorbid
predominant, Cluster 3 – Cardiovascular disease (CVD) /
Diabetes predominant, Cluster 4 – Severe COPD/Frail pre-
dominant and Cluster 5 – Obesity/Atopy predominant.
The dark and light shading on the tables was done by
clinical experts and it is intended to highlight clinically
important information that clinicians would be immedi-
ately interested in. The shading also highlights the vari-
ables mostly drawn on by the clinicians when labelling
the resulting clusters. A comparison of supplementary
variables is shown in Table 3.
Cluster 1 (anxiety/depression predominant)
Small cluster (9% of training set), composed predom-
inantly of young, female smokers, with diagnoses for
anxiety and depression, and an overall highest IMD
score, with 37% of patients at the most deprived
quintile.
Cluster 2 (non-comorbid predominant)
Largest cluster, predominantly male, with roughly equal
numbers of current smokers and ex-smokers. Age at
diagnosis slightly higher than the cohort average. The
Fig. 2 Patient flow diagram. Top level of excluded patient numbers not mutually exclusive. Second level of excluded numbers are given as
applied sequentially
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main feature of this cluster is low rates of most comor-
bidities. Most affluent (highest percentage in 1st IMD
quintile).
Cluster 3 (CVD/ diabetes predominant)
Predominately male cluster of mostly ex-smokers with
high incidence of IHD, heart failure, hypertension, high
eosinophils, diabetes and highest BMI. Patients in this
cluster are the oldest at the age of diagnosis compared
to all other clusters.
Cluster 4 (severe COPD/frailty predominant)
Female, underweight/normal weight patients, mostly
current smokers near the index date. Low prevalence
of cardiovascular comorbidities and high eosinophil
counts. The majority (56%) of all patients in the
training set with severe disease as defined by GOLD
stage IV airflow obstruction were assigned to this
cluster.
Cluster 5 (obesity/atopy predominant)
Predominantly female cluster, small cluster, balanced be-
tween current smokers and ex-smokers. Highest asthma,
CRS, GERD prevalence, second highest anxiety/depres-
sion and cardiovascular comorbidities, most atopic,
mildest GOLD stages and overall high BMI, second
only to cluster 3.
The final clustering solution can be graphically repre-
sented by plotting the three MCA components used in
the analysis. A snapshot of a 3D representation is
shown in Fig. 4. It is evident that the CVD / Diabetes
shares no borders with the Anxiety / Depression or the
Severe COPD clusters, whereas the Anxiety/Depression
cluster shares no border with the Not-comorbid cluster.
However, given this particular low-dimensional
Table 1 Characteristics that were used the analysis: all patients (Entire cohort) and split by training and testing datasetsa
Covariate Level Entire cohort Training cohort Test cohort
n 30,961 23,275 7686
Sex (male) n (%) 16,885 (54.54) 12,723 (54.66) 4163 (54.15)
BMI < 18.5 1305 (4.21) 978 (4.2) 327 (4.25)
≥ 18.5, < 25 9926 (32.06) 7461 (32.06) 2465 (32.07)
≥ 25, < 30 10,358 (33.45) 7758 (33.33) 2600 (33.83)
≥ 30 9372 (30.27) 7078 (30.41) 2294 (29.85)
CRS n (%) 590 (1.91) 445 (1.91) 145 (1.89)
Anxiety n (%) 3123 (10.09) 2375 (10.2) 748 (9.73)
Atopy n (%) 3809 (12.3) 2868 (12.32) 941 (12.24)
Depression n (%) 3413 (11.02) 2605 (11.19) 808 (10.51)
Diabetes n (%) 5001 (16.15) 3789 (16.28) 1212 (15.77)
Eosinophils > 2% n (%) 20,363 (65.77) 15,299 (65.73) 5064 (65.89)
GERD 2759 (8.91) 2108 (9.06) 651 (8.47)
GOLD 1 8077 (26.09) 6017 (25.85) 2060 (26.8)
2 15,536 (50.18) 11,749 (50.48) 3787 (49.27)
3 6322 (20.42) 4730 (20.32) 1592 (20.71)
4 1026 (3.31) 779 (3.35) 247 (3.21)
Heart failure n (%) 4685 (15.13) 3579 (15.38) 1106 (14.39)
Hypertension n (%) 10,515 (33.96) 7906 (33.97) 2609 (33.94)
IHD n (%) 7134 (23.04) 5379 (23.11) 1755 (22.83)
Smoking ex 14,447 (46.66) 10,920 (46.92) 3527 (45.89)
current 16,514 (53.34) 12,355 (53.08) 4159 (54.11)
Therapy type none 11,621 (37.53) 8775 (37.7) 2846 (37.03)
mono 4071 (13.15) 3018 (12.97) 1053 (13.7)
dual 10,261 (33.14) 7722 (33.18) 2539 (33.03)
triple 5008 (16.18) 3760 (16.15) 1248 (16.24)
aBMI Body mass index, CRS Chronic rhinosinusitis, GERD Gastroesophageal reflux disease, IHD Ischaemic heart disease, GOLD Global initiative for chronic
obstructive lung disease
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representation using the first three MCA components,
it becomes clear from Fig. 3 that the clusters are not in
any obvious way visually separable, and therefore
k-means in combination with the Euclidean distance
metric would do no more than segment the dataset
attempting to minimise the distance from the assigned
cluster centres.
Prediction of cluster membership for unseen (test
dataset) cases
The DTC which was trained on 80% of the clustering
training data with the cluster labels as the predicted clas-
ses and the same input of 15 variables as the input to the
MCA. It was able to reach 96% accuracy in classifying un-
seen patients (the remaining 20%) to their respective clus-
ter subgroup. An example graphical representation of the
DTC output is shown in Fig. 5. We applied the DTC on
the test set data and evaluated the performance of cluster-
ing on the clinical validation variables.
The characteristics of the five clusters derived from
the test dataset were comparable to those of the
training dataset with regards to variables included in
the analysis as well as those that were not (Additional
file 1: Tables S3-S5), indicating good reproducibility
of the clusters in unseen data. We applied the full ex-
periment separately on test data and found very good
agreement between the two approaches with a 92%
Jaccard index, meaning that the majority of patients
are allocated to the same clusters in both the DTC
and full MCA/k-means approaches.
Outcomes
Mortality and AECOPD outcomes for all clusters are
summarised in Table 4. Similarly, with previous studies,
Fig. 3 Silhouette plot of all samples resulting from the a HC 5 and b k-means cluster solutions. The dotted line represents the average silhouette
score. Clusters are not annotated with specific labels at this stage
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Table 2 Characteristics of the 5 clusters identified by k-means clustering. Dark and light shading indicates higher and lower
proportions respectively with regards to the entire cohort
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we observed in the overall cohort that the top three re-
corded underlying causes of mortality [34] (by ICD-10
chapters) were respiratory disease (30%) followed closely
by cancer (29%) and circulatory disease (25%).
Five-year cumulative number of AECOPD in primary
care and AECOPD – related hospitalisations for all clus-
ters were calculated and are shown in Fig. 6. The esti-
mated relative hazard ratios for each subgroup resulting
from the Cox proportional hazards regression on CVD
and respiratory-related mortality are summarised in
Table 5.
Cluster 1 (anxiety/depression predominant)
Cluster 1 patients die younger on average and exhibit
the highest rate of AECOPD among all other clusters,
with 27% exacerbating at least once during the first
year after diagnosis. Their hospitalisation rates are
initially average but progress to an increasing rate
(Fig. 6b). They are most likely to die from respiratory
system diseases and are more at risk of death in com-
parison to all other clusters, with the exception of
clusters 3 and 4.
Cluster 2 (non-comorbid predominant)
Age at death for cluster 2 is comparable to the cohort
average. Their acute exacerbation rate is less than aver-
age, while 17% experience at least one exacerbation as
recorded in primary care within the first year after diag-
nosis. Patients assigned to this cluster predominately die
from cancer, whereas their CVD and respiratory mortal-
ity risk is the lowest out of all clusters.
Table 3 Variables not included as input in cluster analysis: Comparison between clusters. Higher IMD score values indicate more
social deprivation (5th quintile is most deprived). Dark and light shading indicates higher and lower proportions respectively with
regards to the entire cohort
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Cluster 3 (CVD/ diabetes)
Patients in cluster 3 have the highest rates of AECOPD
hospitalisation and are most likely to die from circula-
tory system diseases and least likely to die due to cancer
or respiratory related causes. They have the highest aver-
age age at death.
Cluster 4 (severe COPD/frailty predominant)
Patients in cluster 4 show high rates of AECOPD hospi-
talisation and low rates of AECOPD in primary care,
comparable to cluster 3. They are also most likely to die
of cancer and respiratory related causes.
Cluster 5 (obesity/atopy predominant)
Patients in cluster 5 are second only to cluster 1 with
regards to AECOPD exacerbations in primary care and
25% experience at least one AECOPD episode in the
year after their diagnosis. They have on average compar-
able rates of AECOPD hospitalisations to cluster 3 and
are most likely to die of respiratory causes.
Sensitivity analyses
Patients excluded due to missing values had comparable
disease severity and prevalence of comorbidities (where
available), had similar rates of asthma diagnosis and
higher rates of exacerbation in primary and secondary
care. They were also more likely to die from respiratory
related causes (Additional file 1: Tables S6-S8).
A high proportion of patients in the cohort have been
diagnosed with asthma either prior or subsequent to
their COPD diagnosis. The majority of these diagnoses
are expected to be misclassifications, however it is not
generally possible to know whether it was the COPD or
asthma that was incorrectly diagnosed. We therefore
Fig. 5 Simplified example output of decision tree classifier trained with a maximum depth of three
Fig. 4 3D scatter plot of the three MCA Components colour-coded by cluster assignment
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performed the analysis excluding all patients with at least
one asthma diagnostic code. The analysis yielded an
optimal solution of k = 4 clusters, with the atopic cluster
not providing a strong enough signal to form a separate
cluster. The remaining clusters were similar to the original
k5 solution, with over 96% patients being categorised to the
corresponding clusters in both analysis (Anxiety/Depres-
sion, CVD, Not-comorbid, Severe COPD/frail). Patients
belonging to the atopic cluster in the main analysis were
categorised primarily as either Anxiety/Depression patients
(33%) or Not-comorbid (53%). The characteristics of the k4
solution on non-asthmatic patients are shown in Additional
file 1: Table S9.
Discussion
This study identified five COPD clusters using EHR
from primary care. These clusters can be easily identified
from EHR data collected during routine clinical care that
offer longitudinal high-resolution information across dis-
ease states [35, 36]. Individuals within these different
clusters have differing outcomes, underlining the im-
portance of phenotyping individuals with this heteroge-
neous disease more carefully.
The patients most at risk of AECOPD seen in primary
care were female, current smokers and have anxiety and/
or depression (cluster 1). Although the patients in this
cluster initially presented with a lower hospitalisation rate
for exacerbations, they did have a rapid increase in
hospitalisations over time. This is in keeping with our
current understanding of AECOPD; that moderate events
progress to more severe events over time [37]. This cluster
also had lowest average age at death, highlighting the im-
portance of primary care exacerbation events on disease
mortality, and were most likely to die of their COPD. This
may be an important group in which to target prevention
of exacerbation events early on in the course of disease.
Patients in the obesity/atopy predominant cluster
(cluster 5), whilst having similar primary care exacerba-
tion rates to cluster 1 and comparable hospitalisation
rates to cluster 3, did not appear to have a similar in-
crease in hospitalisations for exacerbation events over
time or an increase in mortality or lower age of death
compared to other clusters, suggesting that perhaps
there is something protective about an asthma diagnosis
in this population. This may be related to patient motiv-
ation around disease understanding, healthcare inter-
action or disease management and is a phenomenon
that has been seen in other studies [34]. It is possible
that some of these patients have been misclassified as
having COPD and that is what is driving the trend seen
here. The sensitivity analysis showed that this cluster is
likely not distinctly present when all patients with
asthma are excluded, further supporting the argument
that misclassification of these patients has occurred.
Those patients with comorbid cardiovascular disease
and diabetes unsurprisingly had some of the highest
Table 4 Mortality and AECOPD outcomes: Comparison between clusters. Dark and light shading indicates higher and lower
proportions respectively with regards to the entire cohort
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rates of hospital admission for AECOPD and were most
likely to die of CVD. Interestingly they had the highest
age at time of death and this may be a reflection of the
disease-modifying treatments that are available for CVD
that do not exist to the same extent for COPD. This
cluster also highlights the important role co-morbidity
plays in disease burden and progression. Given that
these patients form a distinct cluster, this provides an
important reason to investigate the presence of CVD
among a COPD population.
The cluster with patients at the second greatest risk
of death were more likely to be female current
smokers. Patients in this cluster were also highly
likely to be hospitalised with an AECOPD. They were
most likely to die of cancer or their COPD. This may
be an important subgroup in which to screen for lung
cancer.
Although therapy type was a covariate included in the
clustering analysis, it did not significantly vary within
clusters and was not identified by the MCA as a variable
that contributes to the overall cohort variance. This is
an indication that, at least in the time-window immedi-
ately before and after diagnosis, therapy decisions are
likely reactive with regards to patients’ early signs of fre-
quent exacerbations.
Two of the identified subtypes correspond well with
the two most reproducible subtypes identified in the
clustering reproducibility analysis [38], which com-
pared clustering results across cohorts: namely (1) a
cluster with severe airflow limitation and low BMI, la-
belled as Severe COPD/frail in this study and (2) a
cluster with high cardiovascular comorbidities and
high BMI, labelled as CVD / Diabetes cluster in this
study.
Previous research identifying clusters in COPD pa-
tients has mostly focused on smaller more specific or
severe populations [7, 8]. However, a recent study by
Burgel et al., using data from several thousand
well-characterised COPD patients followed for three
years, similarly reported clusters of patients with low co-
morbidities, with severe airflow limitation and nutri-
tional depletion, cardiovascular comorbidities, or obesity
[12]. In order to assess its performance on primary care
EHR data, we implemented their proposed simple algo-
rithm. In doing so we had to discard 30% of our dataset
due to high rates of missingness for the mMRC score
variable. Inconsistencies between the mMRC score and
FEV1% predicted as recorded in primary care, led to the
classification results being significantly different to the
original paper, with less than 1% of patients being cate-
gorised as cluster 4 (not comorbid but severe disease), as
opposed to 11% according to the Burgel model and data-
set. This is likely a consequence of the subjective nature
of mMRC score as recorded in the primary care setting.
Table 5 Age-adjusted Cox regression with regards to CVD and
respiratory related mortality
Characteristic Hazard ratio
Age 1.08 [1.07–1.08]
Cluster
Not comorbid 1
Anxiety / depression 1.28 [1.13–1.46]
CVD / diabetes 1.49 [1.38–1.60]
Severe COPD / frail 1.30 [1.20–1.40]
Atopy / obesity 1.15 [1.03–1.30]
A
B
Fig. 6 Cumulative AECOPD episodes by subgroup a in primary care
and b) hospital admissions
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Furthermore, severity plays a significant role in the Bur-
gel model with the result that certain clusters can only
contain specific GOLD stage patients, therefore for some
patients there is less opportunity for their increasing risk
to be picked up while they are at an earlier disease stage.
Limitations
Whilst this study has many strengths, including the large
sample size and ability to determine clusters in a pri-
mary care setting where the majority of COPD is man-
aged in the UK, there are some limitations. Whilst we
used a validated set of Read terms to identify an asthma
diagnosis, and this was seen in clusters with high preva-
lence of atopy, even clusters with the fewest asthma
diagnoses were still close to or above 30%, signifying
high rates of misdiagnosis. Equally the fact that the eo-
sinophils are not highest in this group suggests some
misdiagnosis and this is a well-known problem in pri-
mary care [20]. Secondly, the graphical representation of
patients (Fig. 4) shows that although some clusters are
clearly separable from each other, with no overlapping
boundaries, for others those boundaries are not quite
clear. This is one of the reasons why it should be pos-
sible for complex patients to belong to more than one
cluster. This clustering approach would require a
method that allows for multiple cluster membership in
order to better deal with patients that display temporal
variability with regards to disease severity and progres-
sion, such as for example multimorbid subgroups that
fall between cluster margins. That is not something we
explored in this analysis. In addition, the heterogeneity
of patients still remains even within defined clusters,
most importantly the non-comorbid and severe COPD
clusters and further investigation of the patients belong-
ing to those clusters is required.
Conclusions
We applied cluster analysis to EHR data routinely gener-
ated in primary care, demonstrating that a diagnostic
tool could potentially be developed to distinguish be-
tween COPD subtypes without requiring specialized
testing. The phenotypic depth of the data allows for fur-
ther analysis of significant proportions of the resulting
subgroups, with regards to additional covariates and dis-
ease progression. Further investigation on the within
subgroup variation, as well as the evolution of patient
clusters through time will be the subject of future work.
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